Wakefield Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Wakefield Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$634K	Hold	1,276	–	–	0.14%	171
2026 Q1	$570K	Hold	1,276	–	–	0.15%	161
2025 Q4	$578K	Hold	1,276	–	–	0.16%	157
2025 Q3	$500K	Hold	1,276	–	–	0.14%	151
2025 Q2	$568K	Hold	1,276	–	–	0.16%	154
2025 Q1	$619K	Buy	+1,276	New	+$595K	0.19%	144
2022 Q2	–	Sell	-11,689	Closed	-$3.05M	–	210
2022 Q1	$3.05M	Buy	+11,689	New	+$2.77M	1.09%	24

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wakefield Asset Management's VRTX Position: Q2 2026 in Review

Wakefield Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1,276 shares worth $634K. The position accounts for 0.14% of the portfolio, ranked #171.

Wakefield Asset Management first reported a position in VRTX in Q1 2022 and has held it in 7 quarters since. The position peaked at $3.05M in Q1 2022. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Wakefield Asset Management held 1,276 shares of Vertex Pharmaceuticals worth $634K as of Q2 2026.
Wakefield Asset Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.14% of Wakefield Asset Management's portfolio in Q2 2026, its #171 holding.
Wakefield Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 7 quarters since.
Wakefield Asset Management's Vertex Pharmaceuticals position peaked at $3.05M in Q1 2022.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wakefield Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.